Cephalon's Inc. (CEPH) stock price has shown a consistent improvement over the past six weeks, in addition, it has formed a solid base spanning three months at the 55 level.
Cephalon, Inc., is a biopharmaceutical company, which engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas.
•Good chart pattern.
•Consistent uptrend and rebound from the lows of late August '10.
•Excellent average daily volume of about 1.2 million shares.
•Increased fund interest since June '10.
•Forward P/E ratio is at about 9.
Trading at 64.10, CEPH seems to be a good prospect.